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Abstract
Background: The Gag capsid (CA) is one of the most conserved proteins in highly-diversified human and simian
immunodeficiency viruses (HIV and SIV). Understanding the limitations imposed on amino acid sequences in CA
could provide valuable information for vaccine immunogen design or anti-HIV drug development. Here, by
comparing two pathogenic SIV strains, SIVmac239 and SIVsmE543-3, we found critical amino acid residues for
functional interaction between the N-terminal and the C-terminal domains in CA.
Results: We first examined the impact of Gag residue 205, aspartate (Gag205D) in SIVmac239 and glutamate
(Gag205E) in SIVsmE543-3, on viral replication; due to this difference, Gag206-216 (IINEEAADWDL) epitope-specific
cytotoxic T lymphocytes (CTLs) were previously shown to respond to SIVmac239 but not SIVsmE543-3 infection. A
mutant SIVmac239, SIVmac239Gag205E, whose Gag205D is replaced with Gag205E showed lower replicative ability.
Interestingly, however, SIVmac239Gag205E passaged in macaque T cell culture often resulted in selection of an
additional mutation at Gag residue 340, a change from SIVmac239 valine (Gag340V) to SIVsmE543-3 methionine
(Gag340M), with recovery of viral fitness. Structural modeling analysis suggested possible intermolecular interaction
between the Gag205 residue in the N-terminal domain and Gag340 in the C-terminal in CA hexamers. The
Gag205D-to-Gag205E substitution in SIVmac239 resulted in loss of in vitro core stability, which was recovered by
additional Gag340V-to-Gag340M substitution. Finally, selection of Gag205E plus Gag340M mutations, but not
Gag205E alone was observed in a chronically SIVmac239-infected rhesus macaque eliciting Gag206-216-specific CTL
responses.
Conclusions: These results present in vitro and in vivo evidence implicating the interaction between Gag residues
205 in CA NTD and 340 in CA CTD in SIV replication. Thus, this study indicates a structural constraint for functional
interaction between SIV CA NTD and CTD, providing insight into immunogen design to limit viral escape options.
Background
One of the characteristics of human immunodeficiency
virus (HIV) is to induce persistent viral replication
resulting in AIDS progression. HIV has enormous capa-
city to mutate and escape from host immune recogni-
tion, driving genetic diversification of the circulating
viruses [1-3]. The Gag capsid (CA), comprising the N-
terminal (NTD) and the C-terminal domains (CTD)
[4-6], is one of the most conserved proteins in highly-
diversified HIVs [7]. Understanding structural con-
straints in such viral proteins could provide valuable
i n f o r m a t i o nf o ri m m u n o g e nd e s i g ni nA I D Sv a c c i n e
development.
Virus-specific cytotoxic T-lymphocyte (CTL)
responses play a central role in the control of immuno-
deficiency virus infection [7-12]. CTLs exerting strong
suppressive pressure on HIV replication select for viral
mutations resulting in escape from CTL recognition
[13-16]. Escape mutations in viral proteins with struc-
tural constraints are often selected with viral fitness
costs, possibly facilitating subsequent immune control
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any medium, provided the original work is properly cited.[3,17-23]. Thus, conserved viral proteins such as CA can
be a promising antigen for vaccine-based CTL induction
toward HIV control.
We previously showed vaccine-based control of a
simian immunodeficiency virus mac239 (SIVmac239
[24]) challenge in a group of Burmese rhesus macaques
possessing the major histocompatibility complex class I
(MHC-I) haplotype 90-120-Ia [19,25]. Gag206-216
(IINEEAADWDL) epitope-specific CTL responses play
an important role in this control and select for a CTL
escape mutation, GagL216S, leading to a leucine (L)-to-
serine (S) substitution at the 216th amino acid (aa) in
Gag (CA) with the cost of viral fitness [26]. However,
90-120-Ia-positive vaccinees failed to control a challenge
with another pathogenic SIV strain, SIVsmE543-3 [27],
that has the same Gag206-216 epitope sequence with SIV-
mac239; Gag206-216-specific CTLs did not show
responses against SIVsmE543-3 infection due to an
aspartate (D)-to-glutamate (E) change, GagD205E, at
Gag residue 205 [28].
Thus, the GagD205E substitution in SIVmac239 could
result in viral escape from Gag206-216-specific CTL
recognition. However, in our previous analyses of 90-
120-Ia-positive animals eliciting Gag206-216-specific CTL
responses for one or two years postchallenge, we
observed selection of GagL216S, but not GagD205E
mutation in SIVmac239 infection, suggesting a possibi-
lity that the GagD205E substitution results in larger
reduction of viral replicative ability than GagL216S. In
the present study, we first constructed a mutant SIV-
mac239, SIVmac239Gag205E, with the GagD205E sub-
stitution and examined its replication ability in vitro.
We found that this amino acid change in the CA NTD
results in loss of viral fitness, which can be recovered by
an additional amino acid change in the CA CTD.
Further analyses presented in vitro and in vivo evidence
for a structural constraint in the functional interaction
between SIV CA NTD and CTD.
Results
Compensation for loss of viral fitness in
SIVmac239Gag205E by additional GagV340M substitution
We first constructed a mutant SIVmac239 molecular
clone DNA with a mutation of a D-to-E substitution at
the 205th aa in Gag (CA NTD) to obtain the mutant
virus, SIVmac239Gag205E (Figure 1). Analysis of viral
replication kinetics on HSC-F, a macaque T cell line,
revealed delayed peak of the mutant SIVmac239-
Gag205E replication, indicating its lower replicative abil-
ity compared to the wild-type SIVmac239 (Figure 2).
We further followed up SIVmac239Gag205E replica-
tion on HSC-F cells and explored a possibility of viral
reversion or additional mutations (Figure 3). No addi-
tional gag mutation became dominant on day 10 after
SIVmac239Gag205E infection. Interestingly, however, in
the second culture after passage of the first culture
supernatants on day 10 into uninfected HSC-F cells, an
additional mutation, GagV340M, resulting in a valine
(V)-to-methionine (M) substitution at the 340th aa in
Gag (CA CTD), became dominant in two of four sets of
experiments; SIVmac239 has V while SIVsmE543-3 has
M at the Gag residue 340. The GagD205E mutation
remained dominant, and no other mutations were
detected in the CA-coding region even in the second
culture.
We then constructed a mutant SIVmac239 molecular
clone DNA by introducing the GagV340M mutation
into the SIVmac239Gag205E CA-coding region to
obtain SIVmac239Gag205E340M (Figure 1). This
mutant SIV showed similar replication kinetics on HSC-
F cells with the wild-type SIVmac239, indicating com-
pensation for loss of viral fitness in SIVmac239Gag205E
by addition of the GagV340M substitution (Figure 2).
These results imply that SIV CA with Gag205D-340V or
Gag205E-340M combination is functional whereas the
CA with Gag205E-340V is less functional.
Possible interaction between Gag residues 205 and 340 in
SIV CA hexamers
Recovery of viral fitness of SIVmac239Gag205E by the
GagV340M substitution suggests a possibility of interac-
tion between Gag residues 205 in the NTD and 340 in
the CTD. Modeling of CA monomer structure, however,
showed that the Gag 205th residue is located in the
helix 4 of CA NTD, while the 340th is in the loop
between helices 10 and 11 of CTD, which does not sup-
port a possibility of intramolecular contact between Gag
residues 205 and 340 (data not shown).
CA molecules are known to form hexamer lattice in
mature virions [29-33]. Modeling of CA hexamer struc-
ture revealed that the Gag 205th residue in the NTD is
located in close proximity to the 340th in the CTD of
the adjacent CA molecule (Figure 4). These observations
support a possibility of intermolecular interaction
between Gag residues 205 and 340 in CA hexamers.
In addition, the 312th residue in the loop between
helices 8 and 9 of CTD is located in close proximity to the
205th in the NTD of the adjacent CA molecule. Because
SIVmac239 and SIVsmE543-3 have different amino acids
at this residue 312, alanine (A) in the former and proline
(P) in the latter, we also constructed a mutant SIVmac239
molecular clone DNA by introducing the GagA312P
mutation resulting in A-to-P substitution at the 312th aa
in Gag into the SIVmac239Gag205E CA-coding region to
obtain SIVmac239Gag205E312P (Figure 1). Analysis of
replication kinetics on HSC-F cells indicated recovery of
viral fitness by the additional GagA312P substitution in
SIVmac239Gag205E (Figure 2).
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We then focused on analyzing the possibility of func-
tional interaction between Gag residues 205 in CA NTD
and 312/340 in CA CTD. To confirm differences in viral
fitness among SIVmac239, SIVmac239Gag205E, SIV-
mac239Gag205E312P, and SIVmac239Gag205E340M,
we compared their replicative ability by viral competi-
tion assay (Table 1). The competitions confirmed lower
viral fitness of SIVmac239Gag205E compared to wild-
type SIVmac239, SIVmac239Gag205E312P, and SIV-
mac239Gag340M. SIVmac239Gag205E312P showed
lower viral fitness than SIVmac239, whereas replication
ability of SIVmac239Gag205E340M was no less than the
wild-type. These results indicate that the GagD205E
substitution in SIVmac239 reduced viral fitness, which
was recovered partially by an additional GagA312P and
fully by an additional GagV340M substitution. The com-
petition between SIVmac239 and SIVmac239Ga-
g205E340M at the ratio of 1:1 resulted in selection of
the latter, suggesting that SIV CA with Gag205E-340M
combination observed in SIVsmE543-3 may be slightly
more functional than that with Gag205D-340V in
SIVmac239.
Inhibition of the early phase of SIVmac239Gag205E
replication
We examined whether the GagD205E substitution
affects the early or late phase of SIVmac239 replication.
On LuSIV cells, SIVmac239Gag205E infection showed
significantly lower luciferase activity compared to wild-
type SIVmac239, SIVmac239Gag205E312P, or SIV-
mac239Gag205E340M, indicating suppression of the
early phase of SIVmac239GagD205E replication (Figure
5). In contrast, we did not find a significant difference
in viral production among SIVmac239, SIVmac239-
Gag205E, SIVmac239Gag205E312P, and SIVmac239Ga-
g205E340M (Figure 6). These results indicate that the
loss of viral fitness by the GagD205E substitution is
mainly due to inhibition of the early phase of viral
replication.
Loss of in vitro core stability in SIVmac239Gag205E
If the GagD205E substitution disturbs intermolecular
CA interaction for hexamer formation, it may affect SIV
core stability. To assess the core stability in vitro [34],
concentrated viruses were separated into three fractions
by ultracentrifugation under gradient sucrose
Figure 1 SIV CA amino acid sequences. (A) Comparison of SIVmac239 amino acid sequences in CA, Gag residues 136-364, with SIVsmE543-3
(GenBank accession number U72748). (B) Schema indicating the amino acid substitutions in mutant SIV CA.
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each fraction was subjected to Western blot analysis to
detect CA p27 proteins (Figure 7). In the absence of
Triton X-100, CA proteins were detected in the bottom
fraction, whereas those in the presence of 1% Triton X-
100 were sensitive to the detergent and detected not in
the bottom but only in the top fraction (data not
shown). We compared the in vitro viral core stability
between SIVmac239 and SIVmac239Gag205E in the
presence of 0.6%, 0.9%, and 1.35% Triton X-100, respec-
tively, and found a difference in the presence of 0.6%
Triton X-100. Additional experiments revealed that SIV-
mac239Gag205E core was more sensitive to 0.6% Triton
X-100 treatment than SIVmac239, SIVmac239Ga-
g205E312P, and SIVmac239Gag205E340M (Figure 7).
These results suggest that viral core stability may be
reduced by GagD205E substitution but can be recovered
by additional GagA312P or GagV340M substitution.
Selection of GagD205E plus GagV340M mutations in a
SIVmac239-infected macaque
The GagD205E substitution results in viral escape from
Gag206-216-specific CTL recognition. Finally, we exam-
ined whether this substitution can be selected in the
chronic phase of SIVmac239 infection in 90-120-Ia-posi-
tive macaques eliciting Gag206-216-specific CTL
responses using plasma samples obtained in our pre-
vious experiments [35,36]. SIVmac239-infected 90-120-
Ia-positive macaques select the GagL216S mutation
resulting in viral escape from Gag206-216-specific CTL
recognition, but we found selection of both GagD205E
and GagV340M mutations in viral genomes in one ani-
mal, R01-007 (Table 2). In this animal, GagD205E and
GagV340M mutations were undetectable at week 123
after SIVmac239 challenge, but both became detectable
at week 137 and were dominant at week 150. In con-
trast, the GagL216S mutation dominant at week 123
was not detected at week 150. These results present in
vivo evidence indicating functional interaction between
the Gag 205th residue in NTD and the 340th in CTD of
SIV CA.
Figure 2 Wild-type and mutant SIV replication kinetics in HSC-
F cells. HSC-F cells were infected with SIVmac239 (WT, open
circles), SIVmac239Gag205E (205E, closed diamonds),
SIVmac239Gag205E312P (205E312P, asterisk), or
SIVmac239Gag205E340M (205E340M, open triangles). Virus
production was monitored by measuring RT activity in the culture
supernatants. A representative result from five sets of experiments is
shown.
Figure 3 Passage of SIVmac239Gag205E culture supernatants. HSC-F cells were infected with SIVmac239Gag205E. The culture supernatant
on day 10 was added to fresh HSC-F cells to start the second culture. Viral RNAs were extracted from the first culture supernatant on day 10
and the second culture supernatant on day 16 after the initial infection and subjected to sequence analyses. Dominant amino acid at the 340th
residue remained V on day 10 in all cases but was M on day 16 in two of four sets of experiments (Gag340M was detectable on day 10 in these
two sets of experiments). No other amino acid change was observed in the CA-coding region.
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T h eG a gC Aw h i c hi so n eo ft h em o s tc o n s e r v e dp r o -
teins in HIV and SIV may be a promising immunogen
for CTL-based AIDS vaccines. However, the limitations
imposed on amino acid sequences in CA are not fully
understood. In the present study, we found that the
GagD205E substitution in SIVmac239 CA NTD reduces
viral fitness, which is recovered by additional GagA312P
or GagV340M substitution in the CTD. SIVmac239-
Gag205E passaged in cell culture often resulted in selec-
tion of an additional GagV340M mutation. Furthermore,
selection of Gag205E plus Gag340M mutations, but not
Gag205E alone, was observed in a chronically SIV-
mac239-infected rhesus macaques. These results provide
evidence indicating a functional interaction between
Gag residues 205 in CA NTD and 340 in CA CTD,
Figure 4 Structural models of SIVmac239 CA hexamer. The hexameric SIVmac239 CA models were constructed by homology-modeling
using a crystal structure of the hexameric HIV-1 CA at a resolution of 1.90 Å (PDB code: 3H47[33]) as a modeling template. “MOE-Align” and
“MOE-Homology” in MOE version 2008.1002 were used for the modeling. The side chains of the 205th, 312th, and 340th aa in Gag are shown as
orange sticks. (A) Overall structure of SIVmac239 CA hexamer. (B) The hexameric structures near positions 205, 312, and 340 of wild-type and
mutant SIVmac239 CAs.
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tion between SIV CA NTD and CTD.
HIV and SIV Gag proteins are expressed as unpro-
cessed polyproteins, which are assembled and incorpo-
rated into the virions. Concomitant with viral budding,
incorporated Gag polyproteins are proteolytically
cleaved by viral protease into processed proteins includ-
ing MA (matrix), CA, and NC (nucleocapsid), participat-
ing in mature infectious virion formation [37,38]. Recent
structural analyses [31-33,39-41] indicated that CA pro-
teins form hexamer lattice in matured virions; in the
mature CA core, the intermolecular NTD-NTD and
NTD-CTD interfaces are involved in the formation of
CA hexamers, while the intermolecular CTD-CTD
interface connects neighboring hexamers. Our modeling
analyses did not support a possibility of intramolecular
interaction but indicated possible intermolecular interac-
tion between Gag205 in CA NTD and Gag312/340 in
CA CTD, which may affect CA hexamer formation dur-
ing viral maturation. This is consistent with our results
in Figure 5 indicating that the GagD205E substitution
results in inhibition of the early phase of SIVmac239
replication, which can be overcome by additional
GagA312P or GagV340M substitution. This possibility is
supported also by our results on viral core stability in
vitro, although it remains unclear how much extent the
Table 1 Competition between SIV mutants
a
SIVs in competition Ratio of inoc. titers
b Exp. no. Dominant aa sequences
c
day 6 day 18
4:1 #1 205D 205D
#2 205D 205D
SIVmac239 & SIVmac239Gag205E 1:1 #1 205D 205D
#2 205D 205D
1:4 #1 205D 205D
#2 205D 205D
4:1 #1 205D 312A 205D 312A
#2 205D 312A 205D 312A
SIVmac239 & SIVmac239Gag205E312P 1:1 #1 205D 312A 205D 312A
#2 205D 312A 205D 312A
1:4 #1 205D 312A 205D 312A
#2 205D 312A 205D 312A
4:1 #1 205D 340V 205D 340V
#2 205D 340V 205D 340V
SIVmac239 & SIVmac239Gag205E340M 1:1 #1 205D/E 340V/M 205E 340M
#2 205D/E 340V/M 205E 340M
1:4 #1 205E 340M 205E 340M
#2 205E 340M 205E 340M
4:1 #1 205E 312P 205E 312P
#2 205E 312P 205E 312P
SIVmac239Gag205E & SIVmac239Gag205E312P 1:1 #1 205E 312P 205E 312P
#2 205E 312P 205E 312P
1:4 #1 205E 312P 205E 312P
#2 205E 312P 205E 312P
4:1 #1 205E 340M 205E 340M
#2 205E 340M 205E 340M
SIVmac239Gag205E & SIVmac239Gag205E340M 1:1 #1 205E 340M 205E 340M
#2 205E 340M 205E 340M
1:4 #1 205E 340M 205E 340M
#2 205E 340M 205E 340M
aHSC-F cells were coinfected with two kinds of SIVs indicated. Viral gag fragments were amplified by RT-PCR from viral RNAs from the culture supernatants on
days 6 and 18 postinfection and then sequenced. Results from two sets of experiments (Exp. #1 and #2) are shown.
bThe ratio of the dose (RT activity) of the virus indicated at the top to that at the bottom at coinfection.
cDominant amino acid sequences at the positions where mutations were included in the inoculums are shown. 205D/E, D and E were detected equally at the
205th aa in Gag; 340 V/M, V and M were detected equally at the 340th aa in Gag.
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There has been no report suggesting the influence of
the Gag 205 residue on SIV sensitivity to tripartite inter-
action motif 5a (TRIM5a). A previous report on HIV
CA lattice [31,43] indicated a potential interaction
between the helix 4 of NTD and the loop connecting
helices 10 and 11 of CTD in the adjacent molecule. Our
results suggest the possible involvement of Gag205 and
Gag340 residues in this intermolecular NTD-CTD inter-
action in CA hexamers.
The molecular model of CA hexamers incorporating
the GagD205E substitution suggested shortening of the
distance between Gag205 and Gag340 residues, which
looked to be compensated by GagV340M substitution
(Figure 4). The modeling can draw a hydrophobic
pocket between Gag205 and Gag340 residues in
SIVmac239Gag205E340M as well as SIVmac239, but
not in SIVmac239Gag205E CA hexamers. Thus, this
pocket may be a target candidate for anti-viral drugs.
Both GagL216S and GagD205E mutations can result
in escape from Gag206-216-specific CTL recognition
[19,28], but the former is usually selected in SIV-
mac239-infected 90-120-Ia-positive macaques probably
Figure 5 Mutant SIV infection. LuSIV cells were infected with
SIVmac239 (WT), SIVmac239Gag205E (205E), SIVmac239Gag205E312P
(205E312P), or SIVmac239Gag205E340M (205E340M). Luciferase
activity was measured 24 hr after infection. Relative infectivity is
shown as the ratio (%) of the luciferase activity to that of SIVmac239
(WT). Mean values in three sets of experiments are shown.
Figure 6 Mutant SIV production. COS-1 cells were transfected
with molecular clone DNAs of SIVmac239 (WT), SIVmac239Gag205E
(205E), SIVmac239Gag205E312P (205E312P), or
SIVmac239Gag205E340 M (205E340 M). RT activity of the culture
supernatants two days after transfection was measured. Mean
values in five sets of experiments are shown.
Figure 7 SIV core stability in vitro. Concentrated SIVmac239 (Wt;
lanes 1-3), SIVmac239Gag205E (205E; lanes 4-6),
SIVmac239Gag205E312P (205E312P; lanes 7-9), or
SIVmac239Gag205E340M (205E340 M; lanes 10-12) was separated
into three fractions (top [a], middle [b], and bottom [c]) by
ultracentrifugation under gradient sucrose concentrations in the
presence of 0.6% Triton X-100. Each fraction was subjected to
Western blot analysis to detect SIV CA p27 proteins (A). A
representative result from three sets of experiments is shown. The
bottom (c) fractions were also subjected to RT assay (B).
Table 2 Viral gag sequences in macaque R01-007
infected with SIVmac239
a
Wks after challenge Amino acid sequences
b
at 205th at 216th at 340th
123 D S V
137 D (E) S (L) V (M)
150 E L M
aViral RNAs were extracted from plasma obtained from a 90-120-Ia-positive
macaque R01-007 at weeks 123, 137, and 150 after SIVmac239 challenge. Viral
gag fragments were amplified by RT-PCR from viral RNAs and then
sequenced. This animal showed efficient Gag206-216-specific CTL responses and
vaccine-based control of a SIVmac239 challenge with rapid selection of the
GagL216S escape mutation (at week 5), but accumulated viral mutations in
the chronic phase, leading to reappearance of plasma viremia around week
60 after challenge as described previously [19,35].
bDominant amino acid sequences at the 205th, 216th, and 340th aa in Gag
are shown. Parentheses indicate the sequences that are not dominant but
detectable.
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than the former. In this study, we found selection of
GagD205E plus GagV340M mutations in the chronic
phase of SIVmac239 infection in a 90-120-Ia-positive
macaque. In this animal, the CTL escape GagL216S
mutation first selected after SIVmac239 challenge
became undetectable and was replaced with the CTL
escape GagD205E mutation in combination with
GagV340M in the chronic phase. This may imply that
the GagD205E plus GagV340M mutations might be
more advantageous than the GagL216S mutation for
SIVmac239 replication in the presence of Gag206-216-
specific CTL pressure.
We observed the addition of GagV340M mutation but
not a Gag205E-to-Gag205D reversion in SIVmac239-
Gag205E passage. This may be due to difference in fre-
quencies between purine-to-purine (guanine-to-adenine)
change in the former and purine-to-pyrimidine (ade-
nine-to-thymine) change in the latter. The appearance
of additional GagV340M mutation in SIVmac239-
Gag205E passaged in cell culture as well as the selection
of GagD205E plus GagV340M mutations in an animal
p r o v i d e sk e ye v i d e n c ei n d i c a t ing functional interaction
between Gag residues 205 in CA NTD and 340 in CA
CTD. The Gag is a promising candidate as a vaccine
immunogen for CTL induction, because cumulative stu-
dies have indicated the efficacy of Gag-specific CTL
responses against HIV and SIV infection [7,25,44,45].
H o w e v e r ,v i r a lm u t a t i o n a le s c a p ef r o mC T Lr e c o g n i t i o n
is a major challenge for AIDS vaccine design. Thus, the
information on the structural constraint presented in
this study might be helpful for immunogen design in
AIDS vaccine development.
Conclusions
Our results present in vitro and in vivo evidence impli-
cating the interaction between Gag residues 205 in CA
NTD and 340 in CA CTD in SIV replication. SIV CA
with Gag205D-340V (observed in SIVmac239) or
Gag205E-340M combination (observed in SIVsmE543-3)
is functional whereas the CA with Gag205E-340V is less
functional. Thus, the present study indicates a structural
constraint for functional interaction between SIV CA
NTD and CTD, providing valuable information for
immunogen design to limit viral escape options.
Methods
Analysis of mutant SIV replication
SIV molecular clone DNAs with gag mutations were
constructed by site-directed mutagenesis from the wild-
type SIVmac239 molecular clone DNA [24]. Virus
stocks were obtained by transfection of COS-1 cells
with wild-type or mutant SIV molecular clone DNAs
using Lipofectamine LTX PLUS (Invitrogen, Tokyo,
Japan). Viral titers were measured by reverse transcrip-
tion (RT) assay as described previously [46]. For analysis
of viral replication kinetics, HSC-F cells (herpesvirus sai-
miri-immortalized macaque T-cell line) [47] were
infected with wild-type or mutant SIVs (normalized by
RT activity), and virus production was monitored by
measuring RT activity in the culture supernatants. To
examine viral infectivity, LuSIV cells, which are derived
from CEMx174 cells and contain a luciferase indicator
gene under the control of the SIVmac239 long terminal
repeat, were cultured for 24 hr after viral infection and
then lysed in a reporter lysis buffer (Promega Corp.,
Tokyo, Japan) for measurement of the luciferase activity
in a luminometer (GloMax™ 96 Microplate Lumin-
ometer, Promega Corp.).
Viral competition assay
HSC-F cells were coinfected with two SIVs at a ratio of
1:1 or 1:4, and the culture supernatants harvested every
other day were used for RT assays. On day 6, the super-
natant was added to fresh HSC-F cells to start the sec-
ond culture. Similarly, on day 12 after the initial
coinfection, the second culture supernatant was added
to fresh HSC-F cells to start the third culture. RNAs
were extracted using the High Pure viral RNA kit
(Roche Diagnostics, Tokyo, Japan) from the initial cul-
ture supernatant on day 6 and from the third culture
supernatant on day 18 post-coinfection. The fragment
(nucleotides 1231 to 2958 in SIVmac239 [GenBank
accession number M33262]) containing the entire gag
region was amplified from the RNA by RT-PCR and
sequenced to determine dominant sequences as
described previously [19].
Molecular modeling of hexameric SIVmac239 CA
The crystal structures of HIV-1 CA NTD at a resolution
of 2.00 Å (PDB code: 1M9C[48]), HIV-1 CA CTD at a
resolution of 1.70 Å (PDB code: 1A8O[5]), and hexame-
ric HIV-1 CA at a resolution of 1.90 Å (PDB code: 3H47
[33]) were taken from the RCSB Protein Data Bank [49].
Three-dimensional (3-D) models of monomeric SIV-
mac239 CA were constructed by the homology modeling
technique using ‘MOE-Align’ and ‘MOE-Homology’ in
the Molecular Operating Environment (MOE) version
2008.1002 (Chemical Computing Group Inc., Quebec,
Canada) as described [50,51]. We obtained 25 intermedi-
ate models per one homology modeling in MOE, and
selected the 3-D models which were the intermediate
models with best scores according to the generalized
Born/volume integral methodology [52]. The final 3-D
models were thermodynamically optimized by energy
minimization using an AMBER99 force field [53] com-
bined with the generalized Born model of aqueous solva-
tion implemented in MOE [54]. Physically unacceptable
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Page 8 of 10local structures of the optimized 3-D models were further
refined on the basis of evaluation by the Ramachandran
plot using MOE. The structures of hexameric SIVmac239
CA were generated from the monomeric structures by
MOE on the basis of the assembly information of hex-
americ HIV-1 CA crystal structure [33].
Analysis of viral CA core stability in vitro
Detergent treatment of wild-type and mutant SIV parti-
cles was performed essentially as described previously
[34]. Briefly, viruses from COS-1 cells transfected with
viral molecular clone DNAs (normalized by RT activity)
were concentrated by ultracentrifugation at 35,000 ×
rpm for 75 min at 4°C in a SW41 rotor (Beckman
Instruments, Tokyo, Japan) through a cushion of 20%
sucrose in phosphate buffered saline (PBS). The concen-
trated viral pellets were suspended in PBS. Sucrose step
gradients were prepared in SW55 centrifuge tubes with
the 2.0 ml layer of 60% sucrose on the bottom and 2.1
ml layer of 20% sucrose overlaid. Then, 0.1 ml of Triton
X-100 in PBS and 0.5 ml of concentrated viruses were
overlaid and ultracentrifuged at 35,000 × rpm for 60
min at 4°C in a SW55Ti rotor (Beckman Instruments).
Three fractions (top [a], middle [b], and bottom [c]) of
1.1 ml each were collected from the top and subjected
to Western blot analysis using plasma from a simian-
human immunodeficiency virus 89.6PD-infected rhesus
macaque [55] and RT assay.
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